$Fludarabine-based salvage therapy for refractory/relapsed acute leukemias: A single center experience$

Fludarabine-based salvage therapy for refractory/relapsed acute leukemias: A single center experience

Bibliographic Details
Main Authors:	Abdul Muqtadir Abbasi, Usman Shaikh, Natasha Ali, Mohammad Nadir Haider
Format:	Article
Language:	English
Published:	Elsevier 2021-01-01
Series:	Leukemia Research Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213048921000029

Similar Items

The efficacy of Fludarabine, high dose cytosine arabinoside with granulocyte colony stimulating factor (FLAG) protocol as salvage therapy for Refractory/Relapsed Acute Leukemias in adult Iraqi patients.
by: Alaa Fadhil Alwan, et al.
Published: (2014-08-01)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
by: Bogdan Popescu, et al.
Published: (2019-12-01)

Fludarabine-induced bradycardia in a patient with refractory leukemia
by: Chung-Lo Woei, et al.
Published: (2010-01-01)

Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
by: William Y. K. Hwang, et al.
Published: (2009-01-01)

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
by: Francesco Saraceni, et al.
Published: (2019-04-01)

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
by: Lupini Laura, et al.
Published: (2010-05-01)

Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
by: Marco Montillo, et al.
Published: (2008-03-01)

Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01)

Temozolomide and cisplatin in relapsed/refractory acute leukemia
by: Rasul Muhammad, et al.
Published: (2009-05-01)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
by: Felicitas Thol, et al.
Published: (2021-06-01)

Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia
by: Brandi Anders, et al.
Published: (2017-01-01)

Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis
by: Max S. Topp, et al.
Published: (2021-04-01)

Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi
by: Bongani Kaimila, et al.
Published: (2017-08-01)

Radiopharmaceuticals for Relapsed or Refractory Leukemias
by: Charles A. Kunos, et al.
Published: (2019-02-01)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
by: Nestor R. Ramos, et al.
Published: (2015-04-01)

A Bayesian Network Meta-Analysis Comparing the Efficacies of Eleven Novel Therapies with the Common Salvage Regimen for Relapsed or Refractory Acute Myeloid Leukemia
by: Juan Huang, et al.
Published: (2018-09-01)

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
by: Thumallapally N, et al.
Published: (2016-08-01)

Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience
by: Matteo Piccini, et al.
Published: (2021-04-01)

Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia
by: Jiale Ma, et al.
Published: (2021-01-01)

B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia
by: Meghali Goswami, et al.
Published: (2020-07-01)

Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children
by: NA Batmanova, et al.
Published: (2017-07-01)

Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia
by: Ann Janssens, et al.
Published: (2009-10-01)

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
by: Luca Bertamini, et al.
Published: (2018-11-01)

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
by: Uy N, et al.
Published: (2018-04-01)

Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib- based chemotherapy
by: Zhao J, et al.
Published: (2015-06-01)

T-cell large granular lymphocytic leukemia: treatment experience with fludarabine
by: Renata Oliveira Costa, et al.
Published: (2012-07-01)

Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan
by: Feng-Ming Tien, et al.
Published: (2019-10-01)

Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
by: Serena Chew, et al.
Published: (2020-06-01)

Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date
by: Hathaway L, et al.
Published: (2018-10-01)

Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
by: Ribera JM, et al.
Published: (2015-06-01)

The mortality and response rate after FLANG regimen in patients with refractory/relapsed acute leukemia
by: Vali A Mehrzad, et al.
Published: (2012-01-01)

Cost-effectiveness of gilteritinib for relapsed/ refractory FLT3mut+ acute myeloid leukemia
by: Garnham, A., et al.
Published: (2021)

Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences
by: Ramazan Acar, et al.
Published: (2020-12-01)

The first experience with fludarabine used to treat a patient with refractory Wegener's granulomatosis
by: Vadim Romanovich Gorodetsky, et al.
Published: (2012-04-01)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
by: Matthew E. Tenold, et al.
Published: (2021-03-01)

A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine
by: Darina Ocadlikova, et al.
Published: (2020-09-01)

Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study
by: Federica Lessi, et al.
Published: (2021-08-01)

Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
by: Satoko Oka, et al.
Published: (2021-06-01)

Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia
by: Qingqing Zheng, et al.
Published: (2020-11-01)